• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

News

Article

The Weekly Roundup: August 28-September 1

ICYMI, this week we had articles about lowered infection risks with IL23i and IL-17i, a new trio combination cream for melasma treatment, tralokinumab's success among older patients with AD, and more.

POLL: What Form of Hair Loss Do You Most Commonly Treat in Your Practice?

This Hair Loss Awareness Month, let us know your experiences. Click here to answer this week's poll.

Actual Age Test App Adds Skin Health Evaluation

Actual Age Test App Adds Skin Health Evaluation

Newly Discovered Genes Could Change Vitiligo Treatment

Scientists say the new findings could lead to new drugs for vitiligo and other pigmentation diseases.

Infection Risk Lower With IL-23i and IL-17i Than With TNFi in Psoriasis

Patients with psoriasis treated with IL-23i and IL-17i had a decreased risk of developing pneumonia, otitis media, and upper respiratory tract infections.

POLL: What Treatment Approach Do You Find Most Successful for Improving Melasma?

Click here to answer this week's melasma poll.

5 Ways to Negotiate the Best Physician Employment Contract

There are simple tools that can help us achieve the best employment contract.

New Trio Combination Cream Efficacious in Melasma Treatment

A study found that a triple combination cream containing isobutylamido-thiazolyl-resorcinol, retinoic acid, and dexamethazone proved to be effective in treating melasma.

Study Examines Sun Protection Habits in Sexual and Gender Minority Populations in Lebanon

Investigators recommended further studies exploring the confounding variables that may contribute to higher rates of skin cancers in this patient population.

Follicular Unit Excision Successful in Treating Acne Keloidalis Nuchae

The treated areas remained clear up to 18 months after treatment with follicular unit excision.

Christopher G. Bunick, MD, PhD, Receives 2023 Research Scholar Award

The American Acne and Rosacea Society selected Bunick’s research on tetracycline-class compounds for the award.

Tralokinumab Well-Tolerated Among Older Adults With AD

The post hoc analysis published in JAMA Dermatology studied the safety and efficacy of tralokinumab in adults aged 65 and older.

Further Research Needed to Study Link Between AD and ADHD

Researchers found an association between ADHD and three inflammatory conditions—atopic dermatitis, otitis media, and herpes simplex infection.

Psoriasis Awareness Month 2023: In Review

As Psoriasis Awareness Month 2023 comes to a close, Dermatology Times is reviewing the top psoriasis headlines and news from August.

Pointers With Portela: Skin Health Trivia

In this week’s Pointers With Portela, the 208SkinDoc asks consumers skin health and skin care trivia questions about adequate sleep, SPF reapplication, melasma, and more.

Year-Long Analysis Reveals High Rates of Patient Satisfaction With OnabotulinumtoxinA Treatment

Allergan Aesthetics has shared details of a recently-published analysis involving patient-reported satisfaction, including natural-looking outcomes, with OnabotulinumtoxinA (Botox) treatment.

Nonsurgical Treatment for Nonmelanoma Skin Cancer Exhibits 99% Cure Rate

Image-Guided Superficial Radiation Therapy kills cancer cells without surgery.

FDA Clears Sofwave SUPERB Applicator for the Treatment of Acne Scars

From its clinical study, 97% of patients saw improvement in acne scars after 3 treatment sessions.

Rajani Katta, MD, Discusses the Science Between the Skin/Diet Link

Research continues to show that food plays a large role in skin diseases.

Discovering Dermatology Times: August 2023

Learn more about the in-depth topics covered in the August 2023 issue of Dermatology Times.

Hair Loss Awareness Month 2023: In Review

As Hair Loss Awareness Month 2023 comes to a close, Dermatology Times is reviewing the top hair loss headlines and news from August.

Endo-Radiofrequency Deemed a Safe, Effective Modality for Axillary HS Treatment

The procedure was both effective and safe in a small cohort of patients with refractory hidradenitis suppurativa of the axilla.

Ceramide-Containing Sunscreen Improves Skin Hydration

After 4 weeks of daily use, 92% of participants showed an improvement in skin hydration.

Epidermal AXL Expression Lower in Psoriatic Skin

The findings highlight new data on AXL expression in inflammatory diseases.

Science of Skincare Summit Co-Chairs Preview Cutting-Edge September Program

Patricia Farris, MD, and Ted Lain, MD, MBA, co-chairs of the Science of Skincare Summit, discuss their excitement for the September conference and its innovative educational experience.

Discovering Dermatology Times: August 2023 Acne Vulgaris Supplement

Learn more about the in-depth topics covered in the August 2023 Frontline Forum acne vulgaris supplement of Dermatology Times.

Mechanical Dermabrasion, CO2 Laser Led to Positive Results in Epithelial Sheets Transplantation in Vitiligo

Both modalities achieved positive results and accurate ablation in cultured epithelial sheets transplantation for patients with vitiligo.

POLL: Do You Diagnose and Treat Psoriasis Through Telehealth Appointments?

Click here to answer this week’s poll.

Adult Patients’ Quality of Life, Sexuality Impacted by Childhood Vulvar Lichen Sclerosus Diagnoses

Quality of life and sexuality were somewhat affected in 51.9% of adults who had been diagnosed with vulvar lichen sclerosus in childhood or adolescence.

SFA-002 Phase 1b Trial Shows Positive Results for Treatment of Psoriasis

In the cohort trial, 85% of patients showed an improvement of more than 50 on PASI.


Related Videos
3 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.